President

Erico von Bueren, MD, PhD, MOR (Sakura Finetek USA, Inc.) Dr. Erico von Bueren is the Senior Director of Marketing and Strategy for Sakura Finetek USA, Inc. After his study and Doctorate in Medicine (Milano, Essen, Bochum, Frankfurt, Universities in Italy and Germany) and Masters in Operations Research (Aachen, Germany), Mr. von Bueren started his career in the pharmaceutical industry in medical, product and marketing management in several therapeutic areas (Ferring Pharmaceuticals and Schwarz Pharma/UCB). After 10 years, he switched to the in-vitro diagnostic industry concentrating on the fields of flow cytometry and anatomic pathology (Dako/Agilent, Denmark and U.S.A., and Thermo Fisher Scientific, U.S.A.). Now at Sakura Finetek USA, his focus in commercial and global product and market development resides in automating and standardizing anatomic pathology through continuous innovation.

President-Elect

Shalini Singh, MD (Roche Diagnostics Solutions) Dr. Shalini Singh is a pathologist and is Head of Pathology at Roche Tissue Diagnostics in Tucson, AZ. She has been with Roche for 13 years. Her primary interests include Digital pathology, personalized healthcare, molecular pathology, translational oncology, and immunotherapy. She is licensed physician with expertise in molecular and genetic pathology and companion diagnostics. She is a Fellow of the College of American Pathologists and collaborates with CAP foundation Educational Grant for residents’ rotation at Roche Tissue Diagnostics. She is an expert in strategic partnerships between Pharma and Diagnostics collaboration.

Immediate Past President

Beth Sheppard, MBA, HT(ASCP) Beth Sheppard has worked in both private and academic management of Anatomic Pathology laboratories and industry for the past 30 years. Her passion to influence the pathology profession includes committee involvement at College of American Pathologist (CAP), ASCP, ISO, CLSI and is past President of the National Society of Histotechnology (NSH).

Treasurer

David Ferber, MD (Leica Biosystems) Dr. David Ferber is a pathologist and Senior Medical and Scientific Affairs liaison at Leica Biosystems. He has greater than 20 years of experience in anatomic and clinical practice with special interest/expertise in genitourinary pathology. He has held many roles during his clinical career including director of the autopsy service, supervisor of pathology assistants, transitional resident faculty, pathology representative on Cancer Committee, and member of virtual tumor board project. He is a graduate of University of Wisconsin School of Medicine and Public Health and completed residency at Medical College of Wisconsin. He is a fellow of the College of American Pathologists and member of the Digital Pathology Society. He is a licensed physician particularly interested in digital pathology and innovation eager to take on the challenges of his role as medical science liaison.

Benefactor Director

Jodi Barrientos (Agilent Technologies, Inc.) Jodi Barrientos is the Vice President of Commercial Marketing for the Diagnostics and Genomics Group at Agilent Technologies. She possesses 15 years of experience in diagnostics leadership in the Immunochemistry, Laboratory Automation, Molecular, Pathology and Genomics disciplines. Ms. Barrientos has held positions with Roche Diagnostics, Qiagen, and Agilent Technologies in a variety areas including applications, sales, training, operations and marketing. Her core passion and focus includes commercial efficiency, pathology and molecular market segments, and strategic partnerships between pharma and diagnostics.

Benefactor Director

Melissa Alexander, MD, PhD (Leica Biosystems) Dr. Melissa Alexander is a pathologist and has served as Medical Director at Leica Biosystems for the past year. She has 5 years experience in surgical pathology practice in New York City with a focus in breast pathology. She is a fellow of the College of American Pathologists with additional subspecialty board certification in cytopathology and licensure in New York State. She continues to teach the pathology to medical students at Mount Sinai hospital and serves as the Secretary for the New York Pathological Society. Prior to her medical training, Dr. Alexander started her career in research, completing her Ph.D. in Microbiology at the University of Virginia prior to earning her medical degree at Emory School of Medicine.

Benefactor Director

Joshua Greenlee, MBA, IASSC CBB™, HT/HTL(ASCP)^cm (Sakura Finetek USA, Inc.) Joshua Greenlee is a Senior Product Manager & Laboratory Workflow/Productivity Strategist for Sakura Finetek USA, Inc. He has greater than 20 years of laboratory experience, primarily in anatomic pathology. He holds a Bachelor of Science in Biology, Master of Business Administration specializing in Project Management, and is dual ASCP certified as an HT/HTL(ASCP)cm. In addition to laboratory work, he spent 4 years working in the NAACLS accredited histology program at Phoenix College. He joined Sakura Finetek USA, Inc., in 2015. With his current position, as an IASSC Certified Black Belt in Lean Six Sigma, Joshua focuses on workflow and implementation of innovative automation solutions in anatomic pathology.

Benefactor Director

Robert Lott, HTL(ASCP) (Roche Diagnostic Solutions) Robert Lott is an Access Engagement Leader within the Global Access and Policy (GA&P) team at Roche Diagnostic Solutions/Ventana Medical Systems, Inc. in Tucson, AZ. Mr. Lott has been involved in anatomic pathology at various levels for more than 35 years. He has served as the National Society for Histotechnology (NSH) appointee to the National Accrediting Agency for Clinical Laboratory Sciences (NAACLS) Board of Directors. In addition, he served on the Histotechnology Examination Committee of the American Society of Clinical Pathologists (ASCP). Mr. Lott has a special interest in histology education and certification. He is a current adjunct faculty member for the Histotechnology Training Program at Harford Community College, Bel Air, MD. Mr. Lott also served as a NSH appointee to the CAP/NSH Histotechnology Committee at the College of American Pathologists from 2005 thru 2011and was reappointed to that committee in 2013. Mr. Lott was named the 2010 NSH Histotechnologist of the Year.